Clinical Trial Diversity: ‘How Much More Evidence Do We Need To Move Forward?’
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA seeks research ideas and plans to include demographic subgroup analyses in review templates as some stakeholders call for bolder action to change how companies conduct clinical trials.
You may also be interested in...
FDA Carrots And Sticks Are Best Way To Get Subgroup Data, Advocates Say
Stakeholders tell FDA it should force sponsors to recruit more diverse populations for its clinical trials by refusing to approve applications with inadequate data or expediting those with the necessary information.
PhRMA’s “I’m In” Campaign Looks To Connect Minorities To Studies
Extension of the Clinical Trial Engagement Network is aimed at increased diversity in clinical trials, which is becoming increasingly important as more drugs are targeted at specific groups.
Poziotinib Fails To Get FDA Panel Support Though Members Not As Dubious As Agency
Agency’s recent approval of Enhertu, which has better response rate, sways some panel members to vote against Spectrum’s NSCLC drug. FDA’s Pazdur compares poziotinib’s dosing uncertainty to ‘building a house on quicksand.’